

Oxular announces 3rd UK Patent issued related to its proprietary Ocular Drug Delivery Device

24 April 2019 – Oxular Limited, the Oxford-based retinal therapeutics company, today announced the UK Intellectual Property Office granted GB-B-2548987 in a patent titled “Ophthalmic delivery device.”

GB-B-2548987 provides an ophthalmic delivery device designed to deliver a specific volume of gas through a needle which subsequently administers an active agent containing composition to the suprachoroidal space or supraciliary space. The gas acts to expand the target space to accept the active agent composition.

The invention also provides methods of treatment of an ocular disease or condition accordingly. The invention also provides active agent containing compositions for delivery into the suprachoroidal space or supraciliary space.

We strongly believe this ocular drug delivery technology enables Oxular’s unique treatment approach which aims to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The drug delivery device is paired with companion drug compositions to form a complete system which is engineered to meet the demands of current market trends toward longer treatment durations and less invasive delivery.

Enquiries

Ben Atwell

Tel: +44 (0) 2037 271390

About Oxular Limited

Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The innovative approach aims to increase therapeutic effectiveness, reduce side-effects and minimize frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications (www.oxular.com).